COVID-19 Update: FAQ and Other Information for Clients

United States ex rel. Doe v. Novo Nordisk, Inc., 1:17-cv-00791 (D.D.C.)

Represented whistleblower in an action under False Claims Act alleging off-label marketing and REMS violations, resulting in a $58 million settlement.

Year: 2017

Contact Information